IN THE CLAIMS:

Please cancel claims 7-17, 29, 31-41 and 43-45, without prejudice or disclaimer. Please add the following new claims:

46. (New) An isolated nucleic acid which encodes human (SEQ ID NO: 14), mouse (SEQ ID NO:16), *D. melanogaster* (SEQ ID NO:18), or *C. elegans* (SEQ ID NO:12) presentiin associated membrane protein (PAMP).

(New) The isolated nucleic acid of claim 46, which encodes human PAMP (SEQ ID NO; 14).

48. (New) The isolated nucleic acid of claim 46, which comprises the coding sequence of human (SEQ ID NO:13), mouse (SEQ ID NO: 15) *D. melanogaster* (SEQ ID NO: 17), or *C. elegans* (SEQ ID NO: 11) PAMP.

49. (New) The isolated nucleic acid of claim 48, which comprises the coding sequence of human PAMP (SEQ ID NO:13).

50. (New) A vector comprising the nucleic acid of claim 46, operatively associated with an expression control sequence.

Serial No. 09/541,094 Response to Office Action mailed August 29, 2001 Docket No. 1034/1F812US2

51. (New) An isolated cell transfected with a vector comprising a nucleic acid encoding a PAMP, and an expression control sequence operatively associated with said nucleic acid, wherein said PAMP is capable of interacting with a presention.

52. (New) The solated cell of claim 51, wherein the nucleic acid encodes human (SEQ ID NO: 14), mouse (SEQ ID NO:16), *D. melanogaster* (SEQ ID NO:18), or *C. elegans* (SEQ ID NO:12) PAMP.

53. (New) the isolated cell of claim 52, wherein the nucleic acid comprises the coding sequence of human (SEQ ID NO:13), mouse (SEQ ID NO: 15) *D. Melanogaster* (SEQ ID NO: 17), or *C. elegans* (SEQ ID NO: 11) PAMP.

54. (New) A method for producing PAMP, which method comprises culturing the cell of claim 51 under conditions that permit expression of the PAMP.

55. (New) An isolated nucleic acid encoding a mutant human PAMP, wherein the corresponding wild-type PAMP is capable of interacting with a presentilin protein.

56. (New) The isolated nucleic acid of claim 55, wherein the mutant PAMP has a mutation in an amino acid residue corresponding to an amino acid selected from

Serial No. 09/541,094 Response to Office Action mailed August 29, 2001 the group consisting of C230, D336, Y337, and both D336 and Y337, of human PAMP (SEQ ID No:14).

- 57. (New) The isolated nucleic acid of claim 56, wherein the mutation is selected from the group consisting of C230A, D336A, Y337A, and both D336A and Y337A.
- 58. (New) The isolated nucleic acid of claim 55, wherein the mutant PAMP has a deletion of an amino acid sequence corresponding to an amino acid sequence selected from the group consisting of \$\triangle 312-369\$ and \$\triangle 312-340\$ of human PAMP (SEQ ID NO:14).
- 59. (New) A vector comprising the nucleic acid of claim 55, operatively associated with an expression control sequence.
- 60. (New) An isolated cell transfected with a vector comprising a nucleic acid encoding a mutant PAMP, and an expression control sequence operatively associated with said nucleic acid.

Serial No. 09/541,094 Response to Office Action mailed August 29, 2001 Docket No. 1034/1F812US2 Page 4 61. (New) A method for producing mutant PAMP, which method comprises

culturing the cell of claim 60 under conditions that permit expression of the mutant

PAMP.

62. (New) An isolated cell transfected with a vector comprising a nucleic acid

encoding a human PAMP, and an expression control sequence operatively associated

with said nucleic acid, wherein said human PAMP is capable of interacting with a

presenilin.

63. (New) The isolated cell of claim 62, wherein the nucleic acid encodes SEQ

ID NO: 14.

64. (New) The isolated cell of claim 62, wherein the nucleic acid comprises

the coding sequence of SEQ ID NO:13.

65. (New) A method for producing human PAMP, which method comprises

culturing the cell of claim 62 under conditions that permit expression of the human

PAMP.

Serial No. 09/541,094 Response to Office Action mailed August 29, 2001